Business Context and Reporting Period
This Form 8-K is filed by Cerecor Inc. (not Avalo Therapeutics, Inc.) on August 15, 2016. The report discloses the company's financial results for the second quarter ended June 30, 2016, referencing a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover document for the 8-K filing and does not contain specific numerical data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the referenced press release (Exhibit 99.1), which is not included in the input text.
Material Changes
No material changes versus the prior comparable period are detailed in the provided text, as the specific financial results are not listed.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information furnished in Item 2.02 and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section. No specific guidance, outlook, or risk factors are detailed in the text provided.
Investor Verification Checklist
- Verify the actual financial figures (revenue, net loss, cash position) by reviewing the full text of the press release (Exhibit 99.1) referenced in this filing.
- Confirm that the registrant is Cerecor Inc., noting the discrepancy with the "Avalo Therapeutics, Inc." name in the request metadata.
- Review the full 10-Q filing for the period ended June 30, 2016, for audited or reviewed financial statements and detailed risk factors.